Inhibitors of sodium-glucose cotransporter-2 (SGLT2), an important player in diabetes pathogenesis, were reported to be helpful in treating heart failure and reducing AF risk (reviewed in [117,118]. This evidence concerns the gene SLC5A2 and heart failure.